ReviewPharmacoEconomics1993
Oral ciprofloxacin: a pharmacoeconomic evaluation of its use in the treatment of serious infections.
Review in PharmacoEconomics, 1993. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 39 citations in OpenAlex.
- Cost-effectiveness of abbreviating the duration of intravenous antibacterial therapy with oral fluoroquinolones.PharmacoEconomics · 1997Trial
- Clinical and economic considerations in the use of third-generation oral cephalosporins.PharmacoEconomics · 1995Trial
- Effect of enteral feeding with ensure on oral bioavailabilities of ofloxacin and ciprofloxacin.Antimicrobial agents and chemotherapy · 1994Trial
- Correlating physicochemical and biological properties to define critical quality attributes of a rAAV vaccine candidate.Molecular therapy. Methods & clinical development · 2023Article
- ZIF-8 and Its Magnetic Functionalization as Vehicle for the Transport and Release of Ciprofloxacin.Pharmaceutics · 2022Article
- Hospital-based ciprofloxacin use evaluation in Eastern Ethiopia: a retrospective assessment of clinical practice.The Pan African medical journal · 2021Article
- Intravenous to oral conversion of fluoroquinolones: knowledge versus clinical practice patterns.Pharmacy world & science : PWS · 2002Article
- Detection of ciprofloxacin-resistant Yersinia pestis by fluorogenic PCR using the LightCycler.Journal of clinical microbiology · 2001Article
- The new fluoroquinolones: A critical review.The Canadian journal of infectious diseases = Journal canadien des maladies infectieuses · 1999Article
- Cefpodoxime proxetil. An appraisal of its use in antibacterial cost-containment programmes, as stepdown and abbreviated therapy in respiratory tract infections.PharmacoEconomics · 1996Review
- Ciprofloxacin. An updated review of its pharmacology, therapeutic efficacy and tolerability.Drugs · 1996Review
- Costs, innovation and efficiency in anti-infective therapy.PharmacoEconomics · 1996Review
- Review
- Fleroxacin. A review of its pharmacology and therapeutic efficacy in various infections.Drugs · 1995Review
- Teicoplanin. A pharmacoeconomic evaluation of its use in the treatment of gram-positive infections.PharmacoEconomics · 1995Review
- Ceftazidime. An update of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy.Drugs · 1995Review
- Pharmacoeconomic studies on antibiotics: current controversies.PharmacoEconomics · 1994Article
- Ciprofloxacin. A review of its pharmacological profile and therapeutic use in the elderly.Drugs & aging · 1994Review
- Epidemiology and pharmacoeconomic issues relating to acute respiratory tract infections and acute uncomplicated infections of the urinary tract.PharmacoEconomics · 1994Article
- Sequential antimicrobial therapy: a realistic approach to cost containment?PharmacoEconomics · 1993Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The broad spectrum of antibacterial activity and favourable pharmacokinetic profile of ciprofloxacin permit oral treatment of many serious infections which have traditionally necessitated parenteral antibacterial therapy. This has been demonstrated in comparative studies, in which ciprofloxacin was as effective and well tolerated as standard parenteral therapies (usually aminoglycoside/beta-lactam combinations or broad spectrum cephalosporins) in small numbers of patients with infections of the lower respiratory tract, urinary tract, skin and soft tissue, and bones and joints. Oral ciprofloxacin is considerably less expensive than most parenteral therapies, does not necessitate therapeutic drug monitoring and can be administered on an outpatient basis. In addition, administration by the oral route is more comfortable and convenient for the patient. Pharmacoeconomic studies have confirmed that substitution of oral ciprofloxacin for parenteral therapy in the treatment of serious infections can achieve considerable savings in drug acquisition costs, and labour and supplies associated with parenteral drug administration, and may allow early discharge from hospital, resulting in even greater savings. Mean reductions of 43 to 83% were achieved in antibacterial costs in 3 randomised prospective studies, when patients received oral ciprofloxacin instead of various parenteral agents, from the beginning of treatment, or after 3 days' parenteral therapy. It can be concluded that oral ciprofloxacin offers considerable scope for cost avoidance when appropriately substituted for parenteral therapy in the treatment of serious infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.